IKZF1 and acute lymphoblastic leukemia: Our findings suggest that association of IKZF1 deletion and biallelic loss of CDKN2A with higher BTZ sensitivity may have been a factor that contributed to favorable outcomes in refractory ALL patients treated with BTZ combination therapy in the TACL study at least in part.